Even as regional biotech heavyweight Amgen has weathered investor scrutiny over its most recent trial data, smaller tri-county biotech stocks have come under pressure. With initial public offerings happening earlier and earlier in the research and development pipeline, firms looking to raise capital are increasingly vying for investor dollars, even as the timeline for when…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
